Zobrazeno 1 - 10
of 83
pro vyhledávání: '"398"'
Autor:
Sammy Chebon, Elena Fernandez, Ido Paz-Priel, Thomas Emrich, Elina Asikanius, Peter J. Kuebler, Christophe Schmitt, Tiffany Chang
Publikováno v:
Blood. 132:633-633
Introduction Emicizumab is a bispecific humanized monoclonal antibody given subcutaneously, which bridges FIXa and FX to restore the function of missing FVIIIa in PwHA. It is approved for routine prophylaxis in PwHA with inhibitors of all ages, and i
Autor:
François Lionnet, Françoise Driss, Laurent Savale, Pablo Bartolucci, Bernard Maitre, Marc Humbert, Vincent Audard, Dora Bachir, Jocelyn Inamo, Anoosha Habibi, Gérald Simonneau, Florence Parent, Etienne Audureau, Frédéric Galactéros, Gylna Loko
Publikováno v:
Blood. 132:7-7
Introduction The prospective ETENDARD study (NCT00434902) evaluated 398 outpatients with sickle cell disease (SCD) enrolled between February 2007 and March 2009 at referral centers in France. All patients were homozygous for hemoglobin S or had Sβ0
Autor:
Huafeng Wang, Yiyi Yao, Liping Mao, Yinjun Lou, Yianlin Ren, Xingnong Ye, Min Yang, Liya Ma, Yi Zhang, Yile Zhou, Xin Huang, Yungui Wang, Huan Xu, Hongyan Tong, Hong-Hu Zhu, Jie Jin
Publikováno v:
Blood. 140:3350-3351
Background Therapeutic options remain limited for elderly acute myeloid leukemia (AML) considering the poor tolerance to intensive chemotherapy. Venetoclax in combination with modified intensive chemotherapy has been shown achieved significantly impr
Autor:
Robin Joyce, Rebecca Karp, David Avigan, Ayad Hamdan, Erik J. Uhlmann, Jon E. Arnason, Myrna Nahas, Jacalyn Rosenblatt
Publikováno v:
Blood. 126:5453-5453
Introduction Pure red cell aplasia (PRCA) is a severe consequence of major and bi-directional ABO-mismatched allogeneic stem cell transplantation (allo-SCT), likely the result of persistent isoagglutinin-producing host plasma cells that have escaped
Publikováno v:
Blood. 78:3281-3287
In 1982 a randomized trial of either alternating or syncopated VMCP/VBAP regimens for the treatment of active multiple myeloma was begun (Southwest Oncology Group Study 8229/30). A concurrent investigation was undertaken to evaluate the clinical impo
Autor:
Alessandro Pancrazzi, Enrico Tagliafico, Alessandro Rambaldi, Isabella Bernardis, Giada Rotunno, Cristiana Pascutto, Francisco Cervantes, Rossella Manfredini, Vittorio Rosti, Silvia Salmoiraghi, Virginia Valeria Ferretti, Mario Cazzola, Valentina Artusi, Daniela Pietra, Rhett P. Ketterling, Terra L. Lasho, Tiziano Barbui, Ayalew Tefferi, Naseema Gangat, Annalisa Pacilli, Elisa Rumi, Giovanni Barosi, Paola Guglielmelli, Alberto Bosi, Francesco Passamonti, Animesh Pardanani, Federica Delaini, Alessandro M. Vannucchi, Daniela Cilloni, Margherita Maffioli, Curtis A. Hanson
Publikováno v:
Blood. 124:405-405
BACKGROUND. In primary myelofibrosis (PMF), survival from time of diagnosis is predicted by the international prognostic scoring system (IPSS), and from time of referral, by the dynamic IPSS (DIPSS) or DIPSS-plus. JAK2/CALR/MPL mutational status and
Publikováno v:
Blood. 78(12)
In 1982 a randomized trial of either alternating or syncopated VMCP/VBAP regimens for the treatment of active multiple myeloma was begun (Southwest Oncology Group Study 8229/30). A concurrent investigation was undertaken to evaluate the clinical impo
Publikováno v:
Blood. 108:1851-1851
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T-cell leukemia following IV administration. This phase II study was undertaken to evaluate further the efficacy and safet
Autor:
Tareq Salous, Max J. Gordon, Andrea Sitlinger, Andy Kaempf, Alexey V. Danilov, Geoffrey Shouse, Jonathon B. Cohen, Deborah M. Stephens, Mazyar Shadman, Michael Y. Choi, Matthew Mei, Daniel O. Persky, Carsten Utoft Niemann, Emelie Rotbain, Byung Park, Danielle M. Brander, Brian T. Hill, Krish Patel
Publikováno v:
Blood. 138:2637-2637
Introduction: Comorbidities are common in CLL and associated with shorter overall survival (OS) and disease specific survival (Rotbain, Leukemia, 2021). Using an ensemble machine learning approach, we identified the comorbidities most strongly associ
Publikováno v:
Blood. 138:3756-3756
Introduction: Despite advances in therapy for patients with light-chain (AL) amyloidosis, mortality remains high in the first 6 months after diagnosis in those on treatment (Blood 2017;129:2111). The early deaths are usually sudden cardiac deaths (SC